Low-molecular-weight chitosan scavenges methylglyoxal and Nε-(carboxyethyl) lysine, the major factors contributing to the pathogenesis of nephropathy

Chu Kuang Chou, Shih Ming Chen, Yi Chieh Li, Tzu Chuan Huang, Jen Ai Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Methylglyoxal (MG) can cause protein glycation, resulting in cell damage and dysfunction. Accumulation of MG and its downstream metabolite Nε-(carboxyethyl)lysine (CEL) has been identified in several variations of nephropathy, including diabetic, hypertensive, and gentamicin-induced nephropathies. In this study, we investigated the effects of low-molecular-weight chitosan (lmw-chitosan) on MG-induced carbonyl stress in aristolochic acid-induced nephropathy. We used a buffer to investigate whether MG could be scavenged by lmw-chitosan in vitro. In addition, we also used a mouse model of aristolochic acid-induced nephropathy, which exhibits 12-fold greater accumulation of MG in the kidneys than that found in control animals, to examine whether lmw-chitosan could decrease MG levels in vivo. Examination of the binding of lmw-chitosan with MG in vitro demonstrated that the concentration of lmw-chitosan necessary to achieve 50% inhibition was 4.60 µg mL-1. Treatment with lmw-chitosan (500 mg kg-1 day-1 orally) for 14 days significantly decreased renal MG accumulation from 212.86 ± 24.34 to 86.15 ± 33.79 µg g-1 protein (p < 0.05) and CEL levels from 4.60 ± 0.27 to 2.84 ± 0.28 µmol µg-1 protein (p < 0.05) in the aristolochic acid-induced nephropathy model. These data suggest that lmw-chitosan might represent a novel treatment modality for MG-related diseases such as nephropathy.

Original languageEnglish
Article number312
JournalSpringerPlus
Volume4
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Pyruvaldehyde
Chitosan
Lysine
Molecular Weight
Kidney
Proteins
Diabetic Nephropathies
Gentamicins
Buffers

Keywords

  • Low-molecular-weight chitosan
  • Methylglyoxal
  • N-(carboxyethyl)lysine
  • Nephropathy

ASJC Scopus subject areas

  • General

Cite this

Low-molecular-weight chitosan scavenges methylglyoxal and Nε-(carboxyethyl) lysine, the major factors contributing to the pathogenesis of nephropathy. / Chou, Chu Kuang; Chen, Shih Ming; Li, Yi Chieh; Huang, Tzu Chuan; Lee, Jen Ai.

In: SpringerPlus, Vol. 4, No. 1, 312, 2015.

Research output: Contribution to journalArticle

@article{894ec634c92747788e6a1c940df5ed65,
title = "Low-molecular-weight chitosan scavenges methylglyoxal and Nε-(carboxyethyl) lysine, the major factors contributing to the pathogenesis of nephropathy",
abstract = "Methylglyoxal (MG) can cause protein glycation, resulting in cell damage and dysfunction. Accumulation of MG and its downstream metabolite Nε-(carboxyethyl)lysine (CEL) has been identified in several variations of nephropathy, including diabetic, hypertensive, and gentamicin-induced nephropathies. In this study, we investigated the effects of low-molecular-weight chitosan (lmw-chitosan) on MG-induced carbonyl stress in aristolochic acid-induced nephropathy. We used a buffer to investigate whether MG could be scavenged by lmw-chitosan in vitro. In addition, we also used a mouse model of aristolochic acid-induced nephropathy, which exhibits 12-fold greater accumulation of MG in the kidneys than that found in control animals, to examine whether lmw-chitosan could decrease MG levels in vivo. Examination of the binding of lmw-chitosan with MG in vitro demonstrated that the concentration of lmw-chitosan necessary to achieve 50{\%} inhibition was 4.60 µg mL-1. Treatment with lmw-chitosan (500 mg kg-1 day-1 orally) for 14 days significantly decreased renal MG accumulation from 212.86 ± 24.34 to 86.15 ± 33.79 µg g-1 protein (p < 0.05) and CEL levels from 4.60 ± 0.27 to 2.84 ± 0.28 µmol µg-1 protein (p < 0.05) in the aristolochic acid-induced nephropathy model. These data suggest that lmw-chitosan might represent a novel treatment modality for MG-related diseases such as nephropathy.",
keywords = "Low-molecular-weight chitosan, Methylglyoxal, N-(carboxyethyl)lysine, Nephropathy",
author = "Chou, {Chu Kuang} and Chen, {Shih Ming} and Li, {Yi Chieh} and Huang, {Tzu Chuan} and Lee, {Jen Ai}",
year = "2015",
doi = "10.1186/s40064-015-1106-4",
language = "English",
volume = "4",
journal = "SpringerPlus",
issn = "2193-1801",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Low-molecular-weight chitosan scavenges methylglyoxal and Nε-(carboxyethyl) lysine, the major factors contributing to the pathogenesis of nephropathy

AU - Chou, Chu Kuang

AU - Chen, Shih Ming

AU - Li, Yi Chieh

AU - Huang, Tzu Chuan

AU - Lee, Jen Ai

PY - 2015

Y1 - 2015

N2 - Methylglyoxal (MG) can cause protein glycation, resulting in cell damage and dysfunction. Accumulation of MG and its downstream metabolite Nε-(carboxyethyl)lysine (CEL) has been identified in several variations of nephropathy, including diabetic, hypertensive, and gentamicin-induced nephropathies. In this study, we investigated the effects of low-molecular-weight chitosan (lmw-chitosan) on MG-induced carbonyl stress in aristolochic acid-induced nephropathy. We used a buffer to investigate whether MG could be scavenged by lmw-chitosan in vitro. In addition, we also used a mouse model of aristolochic acid-induced nephropathy, which exhibits 12-fold greater accumulation of MG in the kidneys than that found in control animals, to examine whether lmw-chitosan could decrease MG levels in vivo. Examination of the binding of lmw-chitosan with MG in vitro demonstrated that the concentration of lmw-chitosan necessary to achieve 50% inhibition was 4.60 µg mL-1. Treatment with lmw-chitosan (500 mg kg-1 day-1 orally) for 14 days significantly decreased renal MG accumulation from 212.86 ± 24.34 to 86.15 ± 33.79 µg g-1 protein (p < 0.05) and CEL levels from 4.60 ± 0.27 to 2.84 ± 0.28 µmol µg-1 protein (p < 0.05) in the aristolochic acid-induced nephropathy model. These data suggest that lmw-chitosan might represent a novel treatment modality for MG-related diseases such as nephropathy.

AB - Methylglyoxal (MG) can cause protein glycation, resulting in cell damage and dysfunction. Accumulation of MG and its downstream metabolite Nε-(carboxyethyl)lysine (CEL) has been identified in several variations of nephropathy, including diabetic, hypertensive, and gentamicin-induced nephropathies. In this study, we investigated the effects of low-molecular-weight chitosan (lmw-chitosan) on MG-induced carbonyl stress in aristolochic acid-induced nephropathy. We used a buffer to investigate whether MG could be scavenged by lmw-chitosan in vitro. In addition, we also used a mouse model of aristolochic acid-induced nephropathy, which exhibits 12-fold greater accumulation of MG in the kidneys than that found in control animals, to examine whether lmw-chitosan could decrease MG levels in vivo. Examination of the binding of lmw-chitosan with MG in vitro demonstrated that the concentration of lmw-chitosan necessary to achieve 50% inhibition was 4.60 µg mL-1. Treatment with lmw-chitosan (500 mg kg-1 day-1 orally) for 14 days significantly decreased renal MG accumulation from 212.86 ± 24.34 to 86.15 ± 33.79 µg g-1 protein (p < 0.05) and CEL levels from 4.60 ± 0.27 to 2.84 ± 0.28 µmol µg-1 protein (p < 0.05) in the aristolochic acid-induced nephropathy model. These data suggest that lmw-chitosan might represent a novel treatment modality for MG-related diseases such as nephropathy.

KW - Low-molecular-weight chitosan

KW - Methylglyoxal

KW - N-(carboxyethyl)lysine

KW - Nephropathy

UR - http://www.scopus.com/inward/record.url?scp=84983452323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983452323&partnerID=8YFLogxK

U2 - 10.1186/s40064-015-1106-4

DO - 10.1186/s40064-015-1106-4

M3 - Article

AN - SCOPUS:84983452323

VL - 4

JO - SpringerPlus

JF - SpringerPlus

SN - 2193-1801

IS - 1

M1 - 312

ER -